absk043
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 24, 2021 (NCT04964375)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06668103 | Phase 2 | Dec 30, 2025 | Abbisko Therapeutics Co, Ltd |
| NCT07164170 | Phase 2 | Oct 25, 2025 | Abbisko Therapeutics Co, Ltd |
| NCT07014137 | Phase 2 | Sep 9, 2025 | University of Toronto |
| NCT06632262 | Phase 2 | Nov 13, 2024 | Abbisko Therapeutics Co, Ltd, Fudan University |
| NCT04964375 | Phase 1 | Aug 24, 2021 | Abbisko Therapeutics Co, Ltd, Icon Cancer Center |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbisko Therapeutics Co, Ltd | For profit | 4 | 4 | 2 | 2021 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Icon Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1